Font: Financial Modeling Prep • Jul 02, 2026
On July 2, 2026, analyst firm Roth Capital confirmed its "Buy" rating for Constellation Brands, a major producer of beer, wine, and spirits. This positive investment outlook, issued when the company's stock price was $137.19, is based on the belief that Constellation Brands' financial guidance holds significant potential for future growth within the competitive beverage industry.
This positive outlook for the consumer staples giant is further supported by Constellation Brands' strong first-quarter fiscal 2027 results, where it successfully beat both earnings and revenue forecasts, as reported by Zacks. This robust financial performance is particularly notable because overall net sales actually fell by 3% year-over-year. The decline was a planned strategic result of the company selling some of its wine businesses, optimizing its portfolio.
The company's thriving beer business continues to be its main growth engine, showcasing impressive market performance. Beer sales increased 2% to approximately $2.28 billion, driven by higher shipments and strategic pricing. Specifically, popular brands like Pacifico and Victoria saw a significant increase in depletions, a key metric measuring sales from distributors to retailers and reflecting strong consumer demand in the alcohol industry.
Constellation Brands' financial health appears solid, with its dominant beer division maintaining an impressive 39% operating margin, as highlighted by Seeking Alpha. The company also confirmed its robust forecast for operating cash flow to be between $2.4 billion and $2.5 billion. This strong cash generation is strategically utilized to reward shareholders through consistent dividends and proactive share buybacks, enhancing shareholder returns.
Reflecting this strong financial performance, Constellation Brands raised its earnings per share (EPS) outlook for fiscal 2027. The company's stock valuation is viewed as having significant investment potential, with a forward price-to-earnings (P/E) ratio of around 12x. This key valuation metric compares a company's stock price to its earnings, providing investors with a crucial tool to assess its intrinsic value and future prospects.
|
SOXS§>
Direxion Daily Semiconductor Bear 3X ETF
|
$4.51
16.84%
|
|
LIMN§>
Liminatus Pharma, Inc. Class A Common Stock
|
$0.14
24.13%
|
|
CWD§>
CaliberCos Inc.
|
$1.23
90.61%
|
|
TZA§>
Direxion Daily Small Cap Bear 3X ETF
|
$3.92
2.08%
|
|
BITO§>
ProShares Bitcoin ETF
|
$8.34
2.58%
|
|
SURG§>
SurgePays, Inc.
|
$0.57
38.08%
|
|
NVDA§>
NVIDIA Corporation
|
$194.83
-1.39%
|
|
AAL§>
American Airlines Group Inc.
|
$17.92
-1.27%
|
|
INLF§>
INLIF Limited
|
$0.02
-34.15%
|
|
INTC§>
Intel Corp.
|
$120.35
-5.25%
|